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With advances in genomic sequencing technology, the number of reported gene-disease relationships has rapidly expanded. However,
the evidence supporting these claims varies widely, confounding accurate evaluation of genomic variation in a clinical setting. Despite
the critical need to differentiate clinically valid relationships from less well-substantiated relationships, standard guidelines for such
evaluation do not currently exist. The NIH-funded Clinical Genome Resource (ClinGen) has developed a framework to define and eval-
uate the clinical validity of gene-disease pairs across a variety of Mendelian disorders. In this manuscript we describe a proposed frame-
work to evaluate relevant genetic and experimental evidence supporting or contradicting a gene-disease relationship and the subsequent
validation of this framework using a set of representative gene-disease pairs. The framework provides a semiquantitative measurement
for the strength of evidence of a gene-disease relationship that correlates to a qualitative classification: ‘‘Definitive,’’ ‘‘Strong,’’ ‘‘Moder-
ate,’’ ‘‘Limited,’’ ‘‘No Reported Evidence,’’ or ‘‘Conflicting Evidence.’’ Within the ClinGen structure, classifications derived with this
framework are reviewed and confirmed or adjusted based on clinical expertise of appropriate disease experts. Detailed guidance for
utilizing this framework and access to the curation interface is available on our website. This evidence-based, systematicmethod to assess
the strength of gene-disease relationships will facilitate more knowledgeable utilization of genomic variants in clinical and research
settings.Introduction
The human genome comprises approximately 20,000 pro-
tein-coding genes (see OMIM website in Web Resources),
of which about 3,000 have been reported in association
with at least one Mendelian disease.1 Roughly half1 of
these gene-disease relationships have been identified over
the last decade, as technological advances have made it
possible to use sequence information from small families
or even single individuals to discover new candidate
gene-disease relationships.2,3 However, there is substantial
variability in the level of evidence supporting these claims,
and a systematic method for curating and assessing evi-
dence is needed.
Despite this variability, clinical laboratories may include
genes with preliminary evidence of a gene-disease relation-
ship on disease-targeted panels or in results returned from
exome or genome sequencing. Some of the gene-disease re-
lationships are either unable to be confirmed for many
years or are ultimately proven wrong.4 Evaluating the clin-
ical impact of variants identified in genes with an unclear1Department of Genetics, School of Medicine, University of North Carolina at
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incorrect diagnoses, preventing further evaluations and/or
resulting in errant management of the affected individual
and their families. This scenario highlights the need for a
standardized method to evaluate the evidence implicating
a gene in disease and thereby determine the clinical valid-
ity2 of a gene-disease relationship.
The NIH-funded Clinical Genome Resource (ClinGen)5
is creating an open-access resource to better define clini-
cally relevant genes and variants based on standardized,
transparent evidence assessment for use in precision med-
icine and research. Our group has developed amethod that
(1) qualitatively defines gene-disease clinical validity using
a classification scheme based on the strength of evidence
supporting the relationship and (2) provides a standard-
ized semiquantitative approach to evaluate available evi-
dence and arrive at such a classification. Currently, this
framework is optimized for genes associated with mono-
genic disorders following autosomal dominant, auto-
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inheritance, such as mitochondrial, and diseases with
more complex genomic etiologies, including oligogenic
or multifactorial conditions. Our approach is intended to
neither define multifactorial disease risk nor to be a sub-
stitute for well-established statistical thresholds used for
genome-wide association studies.6,7
This novel framework classifies gene-disease relation-
ships by the quantity and quality of the evidence support-
ing such a relationship. It builds on efforts to catalog
gene-disease associations, such as the Online Mendelian
Inheritance in Man (OMIM) and OrphaNet (see Web Re-
sources), by systematically organizing the supporting and
refuting evidence and then categorizing the strength of ev-
idence supporting these relationships. The resulting clin-
ical validity classifications are valuable to both clinicians
and clinical laboratories. First, they provide insight into
the strength of clinical associations for clinicians interpret-
ing genetic test results for clinical care. Second, they serve
to guide clinical genetic testing laboratories as they
develop disease-specific clinical genetic testing panels or
interpret genome-scale sequencing tests. By including
only those genes with established clinical validity, the
possibility of returning ambiguous, incorrect, or uninfor-
mative results is reduced, improving the quality of inter-
pretation of genomic data.Material and Methods
Qualitative Description: Clinical Validity Classifications
The ClinGen Gene Curation Working Group (GCWG) is
comprised of medical geneticists, clinical laboratory diagnosti-
cians, genetic counselors, and biocurators with broad experience
in both clinical and laboratory genetics. Over the course of 3 years,
this group convened bi-monthly to develop the described frame-
work for assessing gene-disease clinical validity through expert
opinion and working group consensus. We first defined six classes
to qualitatively describe the strength of evidence supporting a
gene-disease association (Figure 1). The amount and type of evi-
dence required for each clinical validity classification builds
upon that of the previous classification level. Evidence used
within this framework to assign a classification to a gene-disease
pair is divided into two main types: genetic evidence and experi-
mental evidence (described below). As evidence is likely to change
over time, any given classification is representative only of the
level of evidence at the time of curation.
The classification ‘‘No Reported Evidence’’ is used for genes that
have not yet been asserted to have a causal relationship with a hu-
man monogenic disorder but may have some experimental data
(e.g., model system data) suggesting a potential role for that
gene in disease. The ‘‘Limited’’ classification requires at least one
variant, asserted to be disease causing, to have plausible genetic ev-
idence to support the association with human disease with or
without gene-level experimental data. ‘‘Moderate’’ classification
encompasses additional clinical evidence (e.g., multiple unrelated
probands harboring variants with potential roles in disease) and
supporting experimental evidence, all of which may be provided
by multiple studies or a single robust study. Replication of the
gene-disease association in subsequent independent publications
and additional substantial genetic and experimental data are crit-896 The American Journal of Human Genetics 100, 895–906, June 1,ical factors for the ‘‘Strong’’ classification. Finally, the hallmark of a
‘‘Definitive’’ gene-disease association is that, in addition to the
accumulation of convincing genetic and experimental evidence,
the relationship has been replicated and ample time has passed
since the initial publication (in general, greater than 3 years) for
any conflicting evidence to emerge. It is important to highlight
that these classifications do not reflect the effect size or relative
risk attributable to variants in a particular gene, but instead the
strength of the evidence. For example, a definitive gene-disease as-
sociation does not imply that a pathogenic variant in that gene
confers 100% penetrance of the phenotype. This metric is not in-
tended to assess the penetrance or risk to develop a disease
outcome.
A gene-disease relationship can be determined to have one of
the above classifications provided no substantial relevant and
valid contradictory evidence exists to call the gene-disease rela-
tionship into question. If such evidence emerges, then the rela-
tionship is described as ‘‘Conflicting Evidence Reported.’’ Types
of contradictory evidence may come from population studies
(such as ExAC8), attempts to experimentally validate the gene-dis-
ease association, or re-analysis of the original family or cohort that
was previously studied. Although the role of a specific variant in a
given disease may be called into question by new evidence, this
may not be sufficient to invalidate the role of the gene in that dis-
ease. Thorough evaluation by experts in the particular disease area
is recommended to determine whether the contradictory evidence
outweighs the existing supportive evidence to classify a gene into
either a ‘‘Disputed’’ or ‘‘Refuted’’ category (see Figure 1 for addi-
tional details).
Semi-Quantitative Assessment of Evidence
Assigning a clinical validity classification to a gene-disease pair re-
quires assessment of the evidence supporting the association. We
developed a semiquantitative approach to evaluate both genetic
(Figure 2) and experimental (Figure 3) evidence in a standardized
manner that promotes consistent collection and weighting of ev-
idence (a detailed standard operating procedure is available on the
ClinGen website; see Web Resources). Development of the quanti-
tative aspect of this framework was based on the qualitative de-
scriptions outlined in Figure 1. Both the qualitative classifications
and their quantitative counterparts were determined by consensus
of the ClinGen Gene Curation Working Group members
comprised of a diverse group of genetics experts and professionals
with additional input from experts in multiple clinical domains.
Throughout development of the framework, several gene-disease
pairs (see Table 1) were iteratively curated as benchmarks with a
known ‘‘anticipated classification’’ to determine appropriate
scores and assigned ranges (e.g., FGFR3 [MIM: 134934]:achondro-
plasia [MIM: 100800]).
Defined sub-categories of genetic and experimental evidence are
given a suggested default ‘‘score.’’ However, given that evidence of
the same general type may vary in its strength (particularly when
considering different diseases), the scoring system also allows
these scores to be adjusted within a set range of points, with final
approval by experts within the particular disease domain. Finally,
the maximum number of points allowed for the various types of
genetic and experimental evidence is capped to prevent a prepon-
derance of weak evidence from inappropriately inflating the
gene-disease classification. Similarly, certain evidence categories
are provided highermaximum scores, allowing key pieces of stron-
ger evidence to proportionately influence the classification of a
gene-disease pair.2017
Figure 1. ClinGen Clinical Validity Classifications and Qualitative Descriptions
The suggestedminimum criteria needed to obtain a given classification are described for each clinical validity classification. The types of
evidence comprising these criteria are described in the text. The default classification for genes without a convincing human disease-
causing variant is ‘‘No Reported Evidence.’’ The level of evidence needed for each supportive gene-disease association category builds
upon the previous category (e.g., ‘‘Limited’’ builds upon ‘‘Moderate’’). Gene-disease associations classified as ‘‘Contradictory’’ likely
have supporting evidence as well as opposing evidence, but are described separately from the classifications for supportive gene-disease
associations.
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Figure 2. Classes of Genetic Evidence and Their Relative Weights Used in the ClinGen Clinical Validity Framework
For additional points to consider when scoring genetic evidence, please see the standard operating procedure document available on our
website. Genetic evidence is separated into two main categories: case-level data and case-control data. While a single publication may
include both case-level and case-control data, individual cases should NOT be included in both categories. Each category is assigned a
range of points with a maximum score that can be achieved. Case-level data are derived from studies describing individuals and/or fam-
ilies with qualifying variants in the gene of interest. Points should be assigned to each case based on the variant’s inheritance pattern,
molecular consequence, and evidence of pathogenicity in disease. In addition to variant evidence points, a gene-disease pair may also
receive points for compelling segregation analysis (see Figure S1). Case-Control Data: Studies utilizing statistical analysis to evaluate var-
iants in case subjects compared to control subjects. Case-control studies can be classified as either single-variant analysis or aggregate
variant analysis, but the number of points allowable for either category is the same. Points should be assigned according to the overall
quality of each study based on these criteria: variant detection methodology, power, bias and confounding factors, and statistical power.
Note that the maximum total scores allowed for different types of case-level data are not intended to add up to the total points allowed
for genetic evidence as a whole. This permits different combinations of evidence types to achieve the maximum total score.Genetic Evidence
For the purposes of scoring, genetic evidence is divided into two
categories: case-level data and case-control data (Figure 2). Studies
describing individuals or families with genetic variants are scored
as case-level data, while studies using statistical analyses to
compare variants in case and control subjects are scored as case-
control data. When case-level and case-control data are present
in a single publication, points can be assigned in each category,
but the same piece of evidence should not be counted more898 The American Journal of Human Genetics 100, 895–906, June 1,than once. For example, an individual case that is also included
within a case-control cohort should not be given points in both
the ‘‘case-level data’’ and ‘‘case-control data’’ categories. In this sce-
nario, points should be assigned to themost compelling and infor-
mative evidence.
Assessing case-level data requires consideration of the inheri-
tance pattern and evaluation of the individual variants identified
in each case. Within this framework, a case should be counted to-
ward supporting evidence only if the reported variant has some2017
Figure 3. Types of Gene-Level Experimental Evidence and Their Relative Weights Used in the ClinGen Clinical Validity Framework
Experimental evidence types used in the ClinGen gene curation framework are modified from MacArthur et al.9 Evidence types are
divided into three categories based on their relative contribution to the overall clinical validity of a gene-disease pair, givingmore weight
to in vivo data. Each category is assigned a range of points with amaximum score that can be achieved, allowingmore weight to be given
(legend continued on next page)
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indication of a potential role in disease (e.g., impact on gene func-
tion, recurrence in affected individuals, etc.), does not have evi-
dence that would contradict pathogenicity (e.g., population allele
frequency), and is of the type consistent with the assumed disease
mechanism (e.g., truncating variant for loss of function). Unless
otherwise noted, the term ‘‘qualifying variant’’ implies that these
criteria are met. In addition, points are assigned separately for
segregation data to reflect the statistical probability that the locus
is implicated in the disease. Figures 2 and S1 provide guidance on
the number of points that should be considered for segregation ev-
idence by LOD score; if a LOD score is not provided within the
publication being evaluated, an estimated LOD score may be
calculated in certain scenarios, as described in the standard oper-
ating procedure document provided on the ClinGen website.
Each study categorized as ‘‘case-control data’’ should be inde-
pendently assessed to evaluate the quality of the study design
(see Figure 2). Consultation with a clinical domain expert group
(such as those affiliated with ClinGen) is recommended. For the
purposes of this framework, studies are classified based on
whether they include single-variant analysis or aggregate variant
analysis. Single-variant analyses are those in which individual var-
iants are evaluated for statistical enrichment in case subject
compared to control subjects. More than one variant may be
analyzed, but the variants have been independently assessed
with appropriate statistical correction for multiple testing. Aggre-
gate variant analyses are those in which the total number of var-
iants is assessed for enrichment in case subjects compared with
control subjects. This comparison is typically accomplished by
sequencing the entire gene in both case and control subjects
and demonstrating an increased ‘‘burden’’ of variants of one or
more types.
Experimental Evidence
The experimental data scoring system is presented in Figure 3. The
gene-level experimental data used in this framework to assess a
gene-disease association are consistent with those proposed by
MacArthur and colleagues to implicate a gene in disease.9 The
following experimental evidence types are used: biochemical
function, experimental protein interactions, expression, func-
tional alteration, phenotypic rescue, and model systems (Figure 3,
bottom). These categories capture the most relevant types of
experimental information necessary to determine whether the
function of the gene product is at least consistent with the disease
with which it is associated, if not causally implicated.
Contradictory Evidence
While curators are encouraged to seek out and document (via qual-
itative description) conflicting evidence, no specific points are as-
signed to this category. The types of valid contradictory evidence
and their relative weights will be unique to each gene-disease
pair, and it would be misleading to attempt to uniformly quantify
this type of negative evidence against the reported positive evi-
dence. If there is substantial conflicting evidence, manual review
and expert input is required to evaluate the strength of the contra-
dictory evidence, determine whether it outweighs any available
supporting evidence, and, if so, decide whether the gene-disease
association should be classified as ‘‘Disputed’’ or ‘‘Refuted.’’to in vivo data (e.g., Models & Rescue) over in vitro experimental dat
and is comprised of the following types of evidence: biochemical fu
ments in cells from affected individuals carrying candidate pathog
Finally, model systems and phenotypic rescue experiments are given
scores allowed for different categories of experimental evidence are n
different combinations of evidence types to achieve the maximum t
900 The American Journal of Human Genetics 100, 895–906, June 1,Summary and Final Matrix
The scores assigned to both genetic and experimental evidence are
tallied to generate a total score (ranging from 1 to 18) that corre-
sponds to a preliminary clinical validity classification (Figure 4).
The system provides a transparent method for summarizing and
assessing all curated evidence for a gene-disease pair, encouraging
consistency between curators. While the summary matrix facili-
tates a preliminary assessment of the gene-disease relationship,
the initial curator or expert reviewer may adjust the classification,
supplying a specific rationale for the change. Final classifications
are determined in collaboration with disease experts, who review
the preliminary classification and supporting evidence and work
to come to a consensus with the preliminary curators. In the event
that the disease experts and preliminary curators disagree on a
final classification, a senior member of the ClinGen Gene Cura-
tion Working Group may be brought in to facilitate a final classi-
fication, erring toward the more conservative classification if
consensus cannot be achieved. It should be noted that experi-
mental data alone cannot justify a clinical validity classification
beyond ‘‘No Reported Evidence,’’ and at least one human genetic
variant with a plausible causal association must be present to
attain ‘‘Limited’’ classification. The difference between ‘‘Limited,’’
‘‘Moderate,’’ and ‘‘Strong’’ gene-disease classifications is justified
by the quality and quantity of evidence; it is expected that valid
gene-disease associations will gradually accumulate enough
supporting evidence and be replicated over time to attain a ‘‘defin-
itive’’ classification. This framework relies predominantly on evi-
dence obtained from published primary literature, identified
through resources such as PubMed and OMIM (see Web Re-
sources), and independently assessed by curators; however, if
necessary, unpublished information available from publicly acces-
sible resources, such as variant databases,10,11 may be used as long
as some supporting evidence is provided.
Results
With this framework, we evaluated 33 gene-disease pairs
representing a variety of disease domains and spanning
the spectrumof clinical validity classifications (see Table 1).
These pairs were intentionally chosen to be representative
of the diversity in monogenic disorders with regards to
inheritance patterns, disease prevalence, and levels of evi-
dence to support a relationship. To assess the reproduc-
ibility of our scoring metric, each gene-disease pair was
evaluated by two independent curators; paired curators
reached concordant clinical validity classifications in 29
of the 31 (93.5%) gene-disease pairs with available pub-
lished evidence (Figure 5; associations classified as ‘‘No
Reported Evidence’’ were excluded). All major discrep-
ancies between curators were discussed and resolved
when possible prior to review by clinical domain experts
(either ClinGen Clinical Domain Working Group
[CDWG] members or ad hoc disease experts mentioneda. Evidence within the function category is given the least weight
nction, interactions, and expression. Functional alteration experi-
enic variants are given more weight than the function category.
the most weight in our framework. Note that the maximum total
ot intended to add up to the total allowable points. This permits
otal score.
2017
Table 1. Categorization of Gene-Disease Pairs Used to Validate the Gene-Validity Framework
Disease Category
HGNC Gene
Symbol
Gene
MIM ID Disease Curated
Inheritance
Pattern
Orphanet ID,
Phenotype MIM ID
Expert Reviewed
Classificationa
Bone marrow failure NHP2 606470 dyskeratosis congenita recessive ORPHA1775, MIM:
613987
limited
RAD51C 602774 Fanconi anemia recessive ORPHA84, MIM:
613390
moderate
RPS10 603632 Diamond-Blackfan
anemia
dominant ORPHA124, MIM:
613308
definitive
RPS24 602412 Diamond-Blackfan
anemia
dominant ORPHA124, MIM:
610629
definitive
TSR2 300945 Diamond-Blackfan
anemia with
mandibulofacial
dysostosis
X-linked ORPHA124, MIM:
300946
limited
WRAP53 612661 dyskeratosis congenita recessive ORPHA1775, MIM:
613988
moderate
Cardiovascular
disorders
AKAP9 604001 Romano-Ward syndrome dominant ORPHA101016, MIM:
611820
limited
SCN4B 608256 long QT syndrome dominant ORPHA768, MIM:
611819
limited
SMAD3 603109 Loeys-Dietz type 3 dominant ORPHA284984, MIM:
613795
definitive
TMPO 188380 familial or idiopathic
dilated cardiomyopathy
dominant ORPHA154, MIM:
613740 b
contradictory (refuted)
Hereditary cancer DICER1 606241 pleuropulmonary
blastoma
dominant ORPHA64742, MIM:
601200
definitive
PALB2 610355 hereditary breast cancer dominant ORPHA227535, MIM:
114480
definitive
PMS2 600259 hereditary pancreatic
cancer
N/A N/A no reported
evidence
RAD51D 602954 hereditary breast cancer dominant ORPHA227535, MIM:
614291
limited
Immune disorders C1QB 120570 immunodeficiency due to
C1Q deficiency
recessive ORPHA169147, MIM:
613652
definitive
CD3E 186830 severe combined
immunodeficiency
recessive ORPHA183660, MIM:
615615
definitive
Skeletal dysplasia ARSD 300002 chondrodysplasia
punctata
N/A N/A no reported
evidence
COL2A1 120140 spondyloepiphyseal
dysplasia (Stanescu type)
dominant ORPHA94068, MIM:
616583
moderate
FGFR3 134934 achondroplasia dominant ORPHA15, MIM:
100800
definitive
LBR 600024 anadysplasia-like,
spontaneously remitting
spondylometaphyseal
dysplasia
recessive ORPHA448267, none moderate
Neuromuscular
disorders
BAG3 603883 myofibrillar myopathy dominant ORPHA593, MIM:
612954
definitive
MYO9A 604875 arthrogryposis recessive ORPHA109007, none limited
PSD3 614440 antecubital pterygium
syndrome
dominant ORPHA2987, none limited
VPS8 N/A arthrogryposis recessive ORPHA109007, none limited
(Continued on next page)
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Table 1. Continued
Disease Category
HGNC Gene
Symbol
Gene
MIM ID Disease Curated
Inheritance
Pattern
Orphanet ID,
Phenotype MIM ID
Expert Reviewed
Classificationa
Miscellaneous AGTR2 300034 X-linked non-syndromic
intellectual disability
X-linked ORPHA777, none contradictory
(disputed)
ATF6 605537 achromatopsia recessive ORPHA49382, MIM:
616517
strong
CHD1L 613039 renal or urinary tract
malformation
dominant ORPHA93545, none limited
HNRNPK 600712 Au-Kline syndrome dominant ORPHA453504, MIM:
616580
moderate
LAMB1 150240 lissencephaly 5 recessive ORPHA352682, MIM:
615191
moderate
NGLY1 610661 x recessive ORPHA404454, MIM:
615273
definitive
SMARCA1 300012 syndromic intellectual
disability with Coffin-
Syris-like features
dominant none, none moderate
SKI 164780 Shprintzen-Goldberg dominant ORPHA311140, MIM:
182212
definitive
SOS2 601247 Noonan syndrome dominant ORPHA648, MIM:
616559
moderate
Abbreviations: N/A, not applicable.
aAll gene-disease classifications are accurate as of January 2017.
bPhenotype MIM was associated with TMPO at the time of curation, but has since been removed due to updated information.in the Acknowledgments); experts agreed with the prelim-
inary classifications for 87.1% (27/31) of the gene-disease
pairs with published evidence (Figure 5). The four discrep-
ancies between the expert and curator classifications were
each different by only a single category (e.g., limited versus
moderate). Of note, the original classifications forHNRNPK
(MIM: 600712) and SMARCA1 (MIM: 300012) were at the
border between limited and moderate (6.5 points); in
each case, the preliminary curators’ lack of specific clinical
expertise led to uncertainty regarding the scoring of evi-
dence requiring such knowledge. Consulting with clinical
experts in the disease resolved these issues, resulting in
both genes being upgraded to moderate. In the case of
WRAP53 (MIM: 612661), the expert was aware of addi-
tional published experimental evidence that when
included increased the classification from limited tomoder-
ate. Upon reviewing the curated evidence for RAD51D
(MIM: 602954) and breast cancer (MIM: 614291), the
domain expert upgraded the classification from disputed
to limited (with the approval of theGCWG)due to the spec-
ificity of the experimental evidence and insufficient power
of the current studies to rule out a role for RAD51D in breast
cancer (Figure 5). Details and references for each curation
are provided in supplemental figures (Figures S2–S65).Discussion
The evidence-based framework described here qualita-
tively defines clinical validity classifications for gene-dis-902 The American Journal of Human Genetics 100, 895–906, June 1,ease associations in monogenic conditions and provides
a systematic framework for evaluating key criteria required
for these classifications. This method is intentionally flex-
ible to accommodate curation of a wide spectrum of genes
and conditions by curators with varying levels of expertise.
The semiquantitative scoring system combined with the
qualitative classification scheme guides curators through
the preliminary decision-making process, while the
expert-level review provides disease-specific experience to
weigh in on the final classification.
This effort to create a generalized framework may result
in some specific challenges due to the heterogeneity of ge-
netic conditions, in both phenotype and prevalence. For
example, conditions that span a large phenotypic spec-
trummay pose a challenge when defining what constitutes
a condition and what is most relevant for curation pur-
poses. In general, ClinGen encourages its expert curation
groups to focus on disease associations that have been as-
serted in the literature or in other authoritative sources
(e.g., OMIM, Orphanet Disease Ontology). Expert re-
viewers may find it useful in certain scenarios to curate
both a syndromic disease association as well as an iso-
lated/non-syndromic disease association limited to a
particular sub-phenotype, for example, when a disease
entity encompasses sub-phenotypes that are caused by
different mutational mechanisms. This is a topic of
continued discourse within the ClinGen working groups
and will be incorporated into future manuscripts that
will focus on the curation approach for individual ClinGen
disease-focused expert groups.2017
Figure 4. Final Summary Matrix Used to Provisionally Classify Gene-Disease Associations
A summary matrix was designed to generate a ‘‘provisional’’ clinical validity assessment using a point system consistent with the qual-
itative descriptions of each classification. Genetic evidence: total number of points (not exceeding 12) obtained using the scoringmetric
in Figure 2. If no human variants associated with disease have been reported in the literature, then the default classification is ‘‘No Re-
ported Evidence.’’ Experimental evidence: total number of points (not exceeding 6) derived from each of the experimental categories in
Figure 3. Replication over time: yes, if more than 3 years has passed since the publication of the first paper reporting the gene-disease
relationship ANDmore than two publications with humanmutations exist. Contradictory evidence: no points are assigned to this cate-
gory; instead, the curator should provide a summary of contradictory information. Scoring: the sum of the quantified evidence from
each category can be used to determine a ‘‘provisional’’ classification using the scale at the bottom of the figure. If a curator does not
agree with this classification, he/she may provide a different suggested classification along with appropriate justification.Ultra-rare disordersmayhave a relatively smallnumberof
probands described in the medical literature, thus limiting
their potential to achieve a high genetic evidence score
within this matrix. This obstacle is mostly circumvented
by allowing compelling pieces of genetic evidence to score
the maximum number of points (for example, see CD3E
[MIM: 186830] and severe combined immunodeficiency
[MIM: 615615] in Figures S14 and S15). When substantial
experimental evidence is also available, these conditions
can attain a ‘‘Strong’’ or ‘‘Definitive’’ classification. On the
opposite end of the spectrum are conditions that occur
commonly in the general population, such as cancer, where
the predominant etiology is multifactorial rather than
monogenic. In the less common Mendelian cancer predis-
position syndromes, incomplete penetrance is a typical
feature that can lead to confounding factors in family ge-
netic studies such as apparently non-penetrant family
memberswho carry a disease-associated variant andpheno-
copies among familymembers without a disease-associatedThe Amevariant. For such conditions, case-control datamay provide
more compelling evidence to support the gene-disease asso-
ciation (see Figures S36 and S37 for PALB2 [MIM: 610355]
andhereditary breast cancer [MIM: 114480] as an example).
One limitation of any such system is the challenge of
balancing thorough literature curation and practical time
commitment. This system can accommodate an exhaus-
tive literature review, but in most cases will require
curating only the amount of information sufficient to
reach the maximum number of points in the matrix. In
some scenarios this method may fail to include pertinent
information, which could impact the classification (e.g.,
omission of contradictory evidence). Another potential
limitation is the subjective nature of certain evidence types
(e.g., experimental), which may lead to variability between
different groups assessing evidence. However, due to the
transparency of the evidence base, the incorporation of
expert review, and the ability to reassess classifications
over time, such drawbacks are likely to be self-limiting.rican Journal of Human Genetics 100, 895–906, June 1, 2017 903
Figure 5. Comparison of Provisional Clinical Validity Classifications and Associated Matrix Scores for Selected Gene-Disease Pairs
Evaluated by Multiple Curators
Of the 33 gene-disease pairs (y axis) curated to validate the clinical validity curation framework, 31 were classified using the summary
matrix (two gene-disease pairs, PMS2:pancreatic cancer and ARSD:chondrodysplasia punctata, were classified as ‘‘No evidence reported’’
(legend continued on next page)
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ClinGen’s ultimate goal is to enhance the incorporation
of genomic information into clinical care, an important
component of the Precision Medicine Initiative.12 The im-
plementation of this framework will be supported by an
open-access ClinGen curation interface (under develop-
ment) that will guide curators through the curation
process and will serve as a platform for extension to the
community. In essence, this framework aims to provide a
systematic, transparent method to evaluate a gene-disease
relationship in an efficient and consistent manner suitable
for a diverse set of users. A detailed standard operating pro-
cedure for this framework is available on the ClinGen
website. All curated evidence, including clinical validity as-
sessments, will also be made readily accessible to clinical
laboratories, clinicians, researchers, and the community
via our website. Additionally, for community members
that wish to contribute papers of interest and/or request
curation of a gene-disease pair, a ‘‘reporter’’ form is avail-
able on the ClinGen website.
Carefullyevaluatedgene-disease clinicalvalidityclassifica-
tions, asprovidedby this framework,will beuseful to clinical
laboratories as they evaluate genes for inclusion on disease-
targeted panels, or as they decide how to categorize, priori-
tize, and return results from exome/genome sequencing.
Cliniciansmaychoose touse these typesofgene-disease clas-
sifications as they interpret laboratory results for the individ-
uals theycare for; for instance, theymaychoosenot toadjust
medical management based on variants in genes of limited
clinical validity. Researchers could also utilize this frame-
work to evaluate the clinical validity of their own newly
discovered associations and identify promising target genes
for future work in order to augment the currently available
evidence and attain a ‘‘Strong’’ or ‘‘Definitive’’ classification.
In addition, professional societies and regulatorybodiesmay
utilize these clinical validity assessments when making rec-
ommendations or guidelines for clinical genetic testing.
Ultimately, our systematic, evidence-basedmethod for eval-
uating gene-disease associations will provide a strong foun-
dation for genomic medicine.Supplemental Data
Supplemental Data include 65 figures and can be found with this
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